Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 9, 2026HaematologicaOpen Access

Breaking barriers in rare disease research: a pilot trial of thromboprophylaxis with apixaban versus aspirin in JAK2-Positive myeloproliferative neoplasms

View Full Paper
Ask AI
Bookmark
Share

Authors

MKMiriam KimptonSCSonia CerquozziDTDominique Toupin

Discussion

Loading...

Member takes

Overview

Pilot trial evaluates thromboprophylaxis in JAK2-positive myeloproliferative neoplasms, suggesting new treatment pathways.

Key Points

  • This pilot trial aims to compare the effectiveness of apixaban versus aspirin for thromboprophylaxis in JAK2-positive myeloproliferative neoplasms.
  • Pilot trial design
  • Participants with JAK2-positive myeloproliferative neoplasms
  • Comparison between apixaban and aspirin interventions
  • Detailed numerical results are not provided due to the lack of abstract information.

Cite This Study

Kimpton et al. (2026) studied this question.

synapsesocial.com/papers/69fecfe9b9154b0b82876e3fhttps://doi.org/10.3324/haematol.2026.301040
View Full Paper
Ask AI
Bookmark
Share